This exploration compares amyloid PET's evolution in Alzheimer's with amino acid PET's potential in brain tumours, suggesting significant implications.
Summary The evolution of amyloid PET in Alzheimer’s disease illustrates the potential path of amino acid PET in neuro-oncology. Initially seen as of limited value, amyloid PET ultimately enhanced diagnostic accuracy, guided management, and became central once therapies demonstrated PET-measured efficacy. Amino acid PET for CNS tumours is at a similar turning point. It refines diagnosis, distinguishes progression from treatment effects and supports treatment planning. As demand grows and tracer access improves, amino acid PET could follow amyloid PET’s trajectory: emerging as a key tool in precision medicine, clinical management, and as a surrogate endpoint in therapeutic trials.
No takes yet. Share an insight, caveat, or question.
Tolboom et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: